Author

N. Portman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

E. Lim· 3 shared A. Yong· 2 shared C. E. Caldon· 2 shared S. Alexandrou· 2 shared A. Belfiore· 1 shared A. J. Nicholls· 1 shared A. Llop-Guevara· 1 shared A. Parker· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Lim

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

C. Gemma, C. Lai, A. Singh, A. Belfiore, N. Portman, H. Z. Milioli, M. Periyasamy, S. Abuelmaaty, A. J. Nicholls, C. Davies, N. R. Patel, G. Simmons, H. Fan, V. Nguyen, L. Magnani, , S. Ali

This study identifies VGLL1 as a driver of resistance to endocrine therapy in ER+ breast cancer and shows that targeting VGLL1/TEAD interaction can inhibit resistant cell growth.

bioRxiv · Nov 29, 2020Cancer Biology

MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer.

N. Portman, H. H. Milioli, S. Alexandrou, R. Coulson, A. Yong, K. J. Fernandez, K. Chia, D. Segara, A. Parker, S. Haupt, Y. Haupt, W. D. Tilley, A. Swarbrick, C. E. Caldon, E. Lim

This study evaluates MDM2 inhibition combined with endocrine therapy and CDK4/6 inhibition in ER-positive breast cancer, showing synergistic anti-tumor effects in resistant models.

bioRxiv · Jun 9, 2020Cancer Biology

Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors

D. Aziz, N. Portman, K. Fernandez, C. Lee, S. Alexandrou, A. Llop-Guevara, A. Yong, A. Wilkinson, C. M. Sergio, D. Ferraro, D. Etemadmoghadam, D. Bowtell, k. Investigators, V. Serra, P. Waring, , C. E. Caldon

The paper identifies cyclin E1 stabilization in BRCA1-mutated breast cancers and shows synergy between CDK2 and PARP inhibitors in treating these cancers.

bioRxiv · Jan 29, 2020Cancer Biology